Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cellectis SA (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CLLS
Nasdaq
8731
https://www.cellectis.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cellectis SA (ADR)
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
- Apr 22nd, 2024 8:30 pm
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
- Apr 10th, 2024 8:30 pm
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
- Apr 8th, 2024 8:30 pm
Monthly information on share capital and company voting rights
- Apr 4th, 2024 8:30 pm
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
- Jan 16th, 2024 9:30 pm
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
- Dec 22nd, 2023 9:30 pm
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
- Nov 17th, 2023 9:30 pm
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
- Nov 15th, 2023 7:30 am
Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript
- Nov 8th, 2023 6:27 pm
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
- Nov 6th, 2023 9:30 pm
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
- Nov 2nd, 2023 8:30 pm
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
- Nov 1st, 2023 8:30 pm
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
- Nov 1st, 2023 7:00 am
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
- Oct 31st, 2023 8:30 pm
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
- Oct 24th, 2023 8:30 pm
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
- Oct 12th, 2023 8:30 pm
These 2 “Strong Buy” Penny Stocks Could Gain Over 500%, Says Baird
- Oct 3rd, 2023 1:55 pm
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
- Sep 27th, 2023 8:30 pm
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
- Aug 7th, 2023 8:30 pm
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
- Aug 3rd, 2023 8:30 pm
Scroll